<?xml version="1.0" encoding="UTF-8"?>
<p id="Par52">Remdesivir is a monophosphoramidate prodrug of an adenosine analogue that inhibits viral RNA synthesis with a broad antiviral spectrum including filoviruses, paramyxoviruses, pneumoviruses, and coronaviruses. There is limited information on adverse effects. However, hypokalemia is a common reported side effect [
 <xref ref-type="bibr" rid="CR52">52</xref>] and there was a patient who developed hypotension and bradycardia when this medication was used to treat Ebola [
 <xref ref-type="bibr" rid="CR45">45</xref>]. The safety and efficacy of remdesivir for the treatment of COVID-19 are being evaluated in multiple ongoing Phase 3 clinical trials. In a recent randomized, double-blind, placebo-controlled, multicenter trial at ten hospitals in Hubei, China, conducted on adult patients admitted to hospital for severe COVID-19 disease, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies [
 <xref ref-type="bibr" rid="CR52">52</xref>].
</p>
